The product is intended for the removal of foreign material such as microorganisms and debris following dermal procedures.
“Within my practice I utilize the Microcyn Technology post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections,” said Michael Gold, MD, a board-certified dermatologist and cosmetic surgeon.
Etaluma, Calif.-based Oculus plans to launch the dermatology product in the U.S. in March 2017.
More articles on supply chain:
Hillary Clinton calls on Mylan to lower EpiPen prices
Medical device, drug recalls soar in Q2
Medical device giant Medtronic takes over HeartWare for $1.1B
